NCT06018181View on ClinicalTrials.gov

Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice

Not yet recruitingOBSERVATIONAL
Enrollment

2,008

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2025

Conditions
Ischemic Stroke, Acute
Interventions
DRUG

Shuxuetong Injection

According to clinical real treatment records

All Listed Sponsors
lead

Dongzhimen Hospital, Beijing

OTHER

NCT06018181 - Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice | Biotech Hunter | Biotech Hunter